(firstQuint)Combined Use of BCG and Interferon Alpha in Bladder Cancer.

 140 eligible patients with high risk superifical bladder cancer would be randomised to receive standard dose BCG, low dose BCG or the combination of low dose BCG and interferon alpha in a schedule of "6+3" weekly intravesical instillations.

 Patients would be closely monitored with cystoscopy and urine cytology and intravenous urograms when indicated.

 Pre-and post-instillation urine samples would be collected for cytokine analysis.

.

 Combined Use of BCG and Interferon Alpha in Bladder Cancer@highlight

To compare the toxicity and efficacy of the combination of BCG and interferon alpha to standard dose and low dose BCG alone in high risk superficial bladder cancer